Doses aux organes à risque en radiothérapie conformationnelle et en radiothérapie stéréotaxique : les poumons
| Autor: | P. Maingon, E. Blais, M. Antoine, N. Pourel, C. Breton-Callu, Mahmut Ozsahin, C. Lefebvre, I. Troussier, J. H. Bourhis, A. Aamarcha, A. Mampuya, M. Gérard, P. Lagarde, B. Pichon, G. Kantor |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Lung
Mean lung dose business.industry Stereotactic body radiation therapy medicine.medical_treatment Dose constraints 030218 nuclear medicine & medical imaging Radiation therapy 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Oncology Lung disease 030220 oncology & carcinogenesis medicine Radiology Nuclear Medicine and imaging Nuclear medicine business Radiation Pneumonitis After treatment |
| Zdroj: | Cancer/Radiothérapie. 21:584-596 |
| ISSN: | 1278-3218 |
| Popis: | Radiation-induced lung disease (RILD) is common after radiation therapy and represents cornerstone toxicities after treatment of thoracic malignancies. From a review of literature, the objective of this article was to summarize clinical and non-clinical parameters associated with the risk of RILD in the settings of normo-fractionated radiotherapy and stereotactic body radiation therapy (SBRT). For the treatment of lung cancers with a normo-fractionated treatment, the mean lung dose (MLD) should be below 15-20Gy. For a thoracic SBRT, V20Gy |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect